Bausch Health Companies Inc. (NYSE:BHC) – Analysts at Truist Financial lowered their Q4 2021 earnings estimates for shares of Bausch Health Companies in a report released on Thursday, January 20th. Truist Financial analyst G. Fraser now forecasts that the company will post earnings per share of $1.05 for the quarter, down from their prior forecast of $1.09. Truist Financial also issued estimates for Bausch Health Companies’ Q1 2022 earnings at $1.13 EPS, Q2 2022 earnings at $1.20 EPS, Q4 2022 earnings at $1.32 EPS and FY2026 earnings at $6.56 EPS. Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, November 2nd. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.07. The company had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.15 billion. Bausch Health Companies had a negative return on equity of 2,440.75% and a negative net margin of 13.85%.
Other research analysts have also recently issued reports about the company. Jefferies Financial Group reiterated a “buy” rating on shares of Bausch Health Companies in a report on Friday, October 1st. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a research report on Tuesday, January 4th. BMO Capital Markets restated a “hold” rating on shares of Bausch Health Companies in a report on Monday, November 8th. Finally, Royal Bank of Canada dropped their price target on shares of Bausch Health Companies from $41.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $36.50.
Why SCG Will Soon Replace Your iPhone
Shares of Bausch Health Companies stock opened at $25.06 on Monday. Bausch Health Companies has a twelve month low of $22.99 and a twelve month high of $34.80. The business has a 50-day moving average price of $26.07 and a 200 day moving average price of $27.42. The firm has a market cap of $8.99 billion, a PE ratio of -7.64, a P/E/G ratio of 0.28 and a beta of 1.64.
In other news, Director Steven D. Miller bought 50,000 shares of the stock in a transaction dated Tuesday, November 30th. The shares were bought at an average cost of $24.24 per share, with a total value of $1,212,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert Spurr sold 3,251 shares of the stock in a transaction on Tuesday, January 18th. The shares were sold at an average price of $26.63, for a total value of $86,574.13. The disclosure for this sale can be found here. 13.75% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Sterling Investment Advisors Ltd. bought a new stake in Bausch Health Companies in the third quarter worth $56,000. Moors & Cabot Inc. acquired a new stake in shares of Bausch Health Companies in the 3rd quarter worth $228,000. CI Investments Inc. acquired a new stake in Bausch Health Companies during the 3rd quarter worth about $73,000. Rockefeller Capital Management L.P. increased its stake in shares of Bausch Health Companies by 1,084.7% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 3,495 shares of the company’s stock valued at $102,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new stake in Bausch Health Companies in the 2nd quarter worth about $107,000. Institutional investors and hedge funds own 71.20% of the company’s stock.
About Bausch Health Companies
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Read More: Special Dividends
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Bausch Health Companies right now?
Before you consider Bausch Health Companies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bausch Health Companies wasn’t on the list.
While Bausch Health Companies currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Q4 2021 EPS Estimates for Bausch Health Companies Inc. Cut by Analyst (NYSE:BHC)